Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.
NexGel Inc (NXGLW) develops advanced hydrogel solutions for medical and cosmetic applications through proprietary electron beam cross-linking technology. This dedicated news hub provides investors and industry professionals with essential updates on the company’s innovations in wound care systems, transdermal delivery platforms, and material science breakthroughs.
Access timely announcements including regulatory milestones, strategic partnerships, product developments, and financial performance. Our curated collection ensures efficient tracking of NXGLW’s progress across key sectors: FDA-cleared medical devices, OTC hydrogel products, and custom manufacturing solutions for healthcare providers.
Discover press releases covering technical achievements, manufacturing expansions, and clinical application studies. All content is verified for accuracy and relevance to support informed analysis of NexGel’s market position in the competitive hydrogel industry.
Bookmark this page for centralized access to NXGLW’s material developments, presented with clarity for both technical experts and general investors. Regularly updated to reflect the company activities shaping next-generation hydrogel applications.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone (U.S. Toll Free: 1-800-343-4849 or International: 1-203-518-9848) or webcast. A replay will be available through May 27, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with code 11159118. The webcast recording will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a specialist in ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, has announced its participation in the upcoming Planet MicroCap Showcase: Vegas 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Wednesday, April 23, 2025, at 9:30 a.m. PT in Track 4 - Loire at the Paris Hotel & Casino, Las Vegas. The event runs from April 22-24, 2025.
Investors interested in one-on-one meetings with Mr. Levy can arrange appointments through Planet Micro representatives or by contacting KCSA Strategic Communications at NEXGEL@KCSA.Com. A webcast of the presentation will be available through the company's investor relations website.
NEXGEL (NASDAQ: NXGL) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $3.04 million, up 181% year-over-year, while full-year revenue hit $8.69 million, increasing 112% compared to 2023.
Key Q4 metrics include gross profit of $1.13 million (37.2% margin) and net loss of $0.85 million. Full-year 2024 showed gross profit of $2.75 million (31.6% margin) with a net loss of $3.28 million. The company achieved over 100% revenue growth for the third consecutive year.
Notable developments include first shipments of SilverSeal® to Cintas, successful growth of the Silly George brand from $2M to $5M+ annual revenue, and partnership with STADA to launch Histasolv in North America. The company projects 2025 revenue guidance of $13 million and expects to achieve positive EBITDA during the year.
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 24, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Interested participants can join via phone at 1-800-245-3047 (U.S. Toll Free) or 1-203-518-9765 (International). A replay will be available through April 3, 2025, accessible at 1-844-512-3921 (U.S.) or 1-412-317-6671 (International) using code 11158402. A webcast replay will be available for 90 days.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.
The company's Chief Executive Officer, Adam Levy, will deliver a presentation on Tuesday, March 25th, 2025, at 9:30 a.m. ET. The two-day conference will take place on March 25-26, 2025, and interested parties can access the webcast through the provided link.
Investors seeking one-on-one meetings with Mr. Levy can arrange appointments through iAccess representatives or by contacting KCSA Strategic Communications.
NEXGEL (NASDAQ: NXGL), a leading provider of medical and over-the-counter products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming Webull Consumer Virtual Webinar. The company's Chief Executive Officer, Adam Levy, will deliver a presentation on February 18, 2025, at 2:40 p.m. ET.
Investors interested in attending can access the webinar through the provided Webull zoom registration link. For those seeking one-on-one meetings with CEO Adam Levy, arrangements can be made through Webull representatives or by contacting KCSA Strategic Communications via email at NEXGEL@KCSA.Com.
NEXGEL (NASDAQ: NXGL) released its shareholder letter and guidance for 2024-2025, projecting Q4 2024 revenue of approximately $3.0 million and full-year 2024 revenue of $8.6 million, marking over 100% growth year-over-year for the third consecutive year. The company expects to generate at least $13 million in revenue for 2025 and achieve positive cash flow from operations.
The company operates in three core segments: contract manufacturing and white label, consumer products, and medical device development. Their consumer products division saw significant growth in 2024, particularly with the Silly George acquisition growing from $2 million to over $5 million in annual revenue. The company's partnership with Stada is progressing well, with their first product Histasolv exceeding projections and two additional product launches expected in H2 2025.
NEXGEL (NASDAQ: NXGL) has appointed Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. McGuire, who brings over 30 years of financial and public company experience, has been consulting with NEXGEL since September 2, 2024. He previously served as CFO for several private and public companies in healthcare, financial services, and manufacturing sectors, and was instrumental in guiding a biotech company to NYSE listing in July 2022.
The current CFO, Adam E. Drapczuk III, will transition to a consulting role with the company through his firm, Achieving Consulting Excellence, McGuire, a former Price Waterhouse CPA and Notre Dame graduate, will lead NEXGEL's finance functions as part of the executive management team. The appointment comes as NEXGEL, a provider of medical and OTC hydrogel products, continues to experience high growth.
NEXGEL (NASDAQ: NXGL), a provider of medical and OTC products specializing in ultra-gentle, high-water-content hydrogels, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Winter Conference 2024.
Chief Executive Officer Adam Levy will deliver a presentation on Tuesday, December 10th at 10:30 a.m. ET. The two-day conference will take place on December 10-11, 2024. Interested parties can access the webcast presentation through the provided link, and one-on-one investor meetings can be arranged through iAccess representatives or KCSA Strategic Communications.
FAQ
What is the current stock price of Nexgel Wt Exp 120126 (NXGLW)?
